Image: Vaccine. Archival photo.
Alexander Gintsburg, Director of the N. F. Gamaleya National Research Center for Epidemiology and Microbiology, has announced that patients could potentially begin receiving the experimental Russian mRNA cancer vaccine in late September or mid-October 2025.
“According to the current operational plan, if it is fully implemented, the first group of oncology patients with melanoma should start receiving this preparation in approximately two months,” Gintsburg informed reporters. “This means the period between late September and mid-October, within an experimental framework.”
Gintsburg further indicated that, if successful, the mRNA vaccine technology has the potential to be scaled and applied to other types of cancer beyond melanoma.
“The next set of issues planned for discussion today pertains to broadening the spectrum of cancer patients who can benefit from treatment using this technology. This will primarily involve enhancing the software, which is currently, as is known, configured for oncological diseases exhibiting very high genetic variability, such as melanomas and small-cell lung cancer,” he elaborated during a scientific and technical council meeting at the mRNA Technology Development Center, hosted by Kazan Federal University.
He also highlighted that numerous diseases exist where the number of mutations is considerably lower, providing examples such as pancreatic cancer, prostate cancer, and certain forms of kidney cancer.
“Therefore, it is unequivocally essential to program all stages for the proper presentation of neuroantigens to the immune system,” Gintsburg concluded, emphasizing the intricate biological programming required for broader application.
